PDS Biotech reports preclinical flu vaccine data with Infectimune at IMMUNOLOGY2025

PDS Biotechnology Corp

Infectimune-based flu vaccine elicited multifunctional, influenza-specific CD4 T cells with cytotoxic characteristics in preclinical studies.
Preclinical ferret studies showed neutralization of H3N2 influenza strains from 2014 to 2021 using COBRA antigens.
Studies were funded by NIAID's CIVR-HRP and presented by Dr. Sant (U of Rochester) and Dr. Allen (Cleveland Clinic).
Company reaffirms focus on VERSATILE-003 Phase 3 trial for Versamune HPV in HPV16-positive HNSCC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.